Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1.
The progressive myoclonus epilepsies, featuring the triad of myoclonus, seizures, and ataxia, comprise a large group of inherited neurodegenerative diseases that remain poorly understood and refractory to treatment. The Cystatin B gene is mutated in one of the most common forms of progressive myoclonus epilepsy, Unverricht-Lundborg disease (EPM1). Cystatin B knockout in a mouse model of EPM1 triggers progressive degeneration of cerebellar granule neurons. Here, we report impaired redox homeostasis as a key mechanism by which Cystatin B deficiency triggers neurodegeneration. Oxidative stress induces the expression of Cystatin B in cerebellar granule neurons, and EPM1 patient-linked mutation of the Cystatin B gene promoter impairs oxidative stress induction of Cystatin B transcription. Importantly, Cystatin B knockout or knockdown sensitizes cerebellar granule neurons to oxidative stress-induced cell death. The Cystatin B deficiency-induced predisposition to oxidative stress in neurons is mediated by the lysosomal protease Cathepsin B. We uncover evidence of oxidative damage, reflected by depletion of antioxidants and increased lipid peroxidation, in the cerebellum of Cystatin B knock-out mice in vivo. Collectively, our findings define a pathophysiological mechanism in EPM1, whereby Cystatin B deficiency couples oxidative stress to neuronal death and degeneration, and may thus provide the basis for novel treatment approaches for the progressive myoclonus epilepsies.
Lehtinen
Maria K
MK
Folkhälsan Institute of Genetics, Department of Medical Genetics and Neuroscience Center, University of Helsinki, 00290 Helsinki, Finland.
Tegelberg
Saara
S
Schipper
Hyman
H
Su
Haixiang
H
Zukor
Hillel
H
Manninen
Otto
O
Kopra
Outi
O
Joensuu
Tarja
T
Hakala
Paula
P
Bonni
Azad
A
Lehesjoki
Anna-Elina
AE
D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D002401:Cathepsin B; D016923:Cell Death / Q000235:genetics; D002478:Cells, Cultured; D002531:Cerebellum / Q000473:pathology; D003542:Cystathionine gamma-Lyase / Q000172:deficiency*; D004195:Disease Models, Animal; D018450:Disease Progression; D005697:Galactosides / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000235:genetics; D018698:Glutamic Acid / Q000494:pharmacology; D049452:Green Fluorescent Proteins / Q000235:genetics; D006861:Hydrogen Peroxide / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D016877:Oxidants / Q000494:pharmacology; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000235:genetics*; D034741:RNA, Small Interfering / Q000494:pharmacology; D051381:Rats; D014162:Transfection / Q000379:methods; D020194:Unverricht-Lundborg Syndrome / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*
D005697:Galactosides; D016877:Oxidants; D034741:RNA, Small Interfering; C007816:beta-galactoside; D049452:Green Fluorescent Proteins; D018698:Glutamic Acid; D006861:Hydrogen Peroxide; D002401:Cathepsin B; C400145:cystalysin; D003542:Cystathionine gamma-Lyase